Top Page
Cross Country Healthcare
(NASDAQ:CCRN)
Cross Country Healthcare (CCRN) vs. SPDR S&P 500 ETF (SPY)
Cross Country Healthcare Business Overview & Revenue Model
Cross Country Healthcare Earnings Call Summary
Cross Country Healthcare Financial Statement Overview
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Cross Country Healthcare Technical Analysis
Cross Country Healthcare Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ― | ― | ― | ― | ― | ― | |
69 Neutral | $1.14B | 16.58 | -1.69% | ― | 12.48% | -9.28% | |
62 Neutral | $1.22B | 54.15 | 2.93% | ― | 68.17% | -85.42% | |
60 Neutral | $443.60M | 0.82 | -31.57% | ― | 0.74% | ― | |
55 Neutral | $304.77M | -2.77 | -24.30% | ― | -22.14% | -787.87% | |
52 Neutral | $730.32M | -6.34 | -35.90% | ― | -11.42% | -617.31% | |
43 Neutral | $248.92M | -0.70 | -116.65% | ― | 5.21% | 5.21% |
Cross Country Healthcare Corporate Events
Cross Country Healthcare reported that on March 4, 2026, it released fourth-quarter and full-year 2025 results marked by a 24% year-over-year revenue decline in the quarter to $236.8 million and a 22% drop for the year to $1.05 billion, alongside a sharply wider net loss of $82.9 million in Q4 and $94.9 million for 2025 driven largely by a $77.9 million goodwill and trade name impairment and a $29.6 million deferred tax valuation allowance. Despite continued positive operating cash flow, a strong debt-free balance sheet with about $109 million in cash, share repurchases equivalent to 2.5% of outstanding stock, and broad adoption of its Intellify platform, the company faced a challenging market for travel staffing and disruption from a terminated merger with Aya, even as management signaled a renewed focus on technology-driven growth and cost savings from a 21% U.S. headcount reduction and its India center of excellence.
The most recent analyst rating on (CCRN) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Cross Country Healthcare stock, see the CCRN Stock Forecast page.
On February 23, 2026, Cross Country Healthcare, Inc. announced that it will participate in two investor conferences in March, underscoring its effort to engage with the financial community and highlight its healthcare labor technology platform. The company will attend the Truist Securities Virtual Human Capital Conference on March 12-13, 2026, and the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-19, 2026, with its CFO and head of investor relations conducting one-on-one meetings but making no formal presentations, signaling a focus on targeted investor outreach rather than broad public showcases.
The most recent analyst rating on (CCRN) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Cross Country Healthcare stock, see the CCRN Stock Forecast page.
Cross Country Healthcare, Inc., a technology-driven healthcare workforce solutions provider, specializes in an AI-enabled, cloud-based workforce and vendor management platform that supports hospitals and health systems in managing per diem staffing, internal float pools, and broader labor optimization. Its Intellify platform is designed to enhance workforce visibility, streamline reporting and workflows, and support data-driven decisions that reduce labor costs while sustaining high-quality clinical outcomes.
On February 12, 2026, Cross Country Healthcare announced it would hold a conference call on March 4, 2026, to discuss its fourth quarter and full-year 2025 financial results, with an earnings release scheduled after the market close that same day. The call, which will be webcast and made available for replay, signals an upcoming update on the company’s financial performance and operational trajectory, providing investors and other stakeholders with insight into how its workforce solutions strategy is translating into results.
The most recent analyst rating on (CCRN) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Cross Country Healthcare stock, see the CCRN Stock Forecast page.
Cross Country Healthcare, Inc.’s board of directors scheduled the company’s 2026 Annual Meeting of Stockholders as a virtual-only event to be held on May 11, 2026, moving it more than 30 days earlier than the anticipated anniversary date of the 2025 annual meeting. Because of this change in timing, the company revised the deadlines for stockholder actions: proposals for inclusion in the proxy statement under SEC Rule 14a-8 must be received at its Boca Raton, Florida headquarters by the close of business on March 11, 2026; advance-notice proposals of business or board nominees under the company’s bylaws must be delivered by February 10, 2026; and stockholders intending to solicit proxies for alternative director nominees under the universal proxy rules must provide the required notice by March 12, 2026, ensuring investors and activists have clear timelines for influencing governance and board composition at the 2026 meeting.
The most recent analyst rating on (CCRN) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Cross Country Healthcare stock, see the CCRN Stock Forecast page.
On December 15, 2025, Cross Country Healthcare announced the departure of John A. Martins as President and CEO, effective December 14, 2025. Kevin C. Clark, the company’s co-founder and current Chairman, has been appointed as the new President and CEO. This leadership change is seen as a strategic move to usher in a new era of growth and innovation, particularly following the termination of a transaction with Aya Healthcare. Clark’s extensive experience in the healthcare staffing industry is expected to drive the company towards sustainable, long-term profitable growth.
The most recent analyst rating on (CCRN) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Cross Country Healthcare stock, see the CCRN Stock Forecast page.
On December 9, 2025, Cross Country Healthcare held its Annual Meeting of Stockholders where several key proposals were voted on. The stockholders approved the election of directors for a one-year term, ratified the appointment of Deloitte & Touche as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved the compensation of named executive officers on an advisory basis.
The most recent analyst rating on (CCRN) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Cross Country Healthcare stock, see the CCRN Stock Forecast page.